Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer?: A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab

OBJECTIVE: To evaluate whether building upon multidrug chemotherapy regimens represents a viable strategy in pancreatic cancer clinical trial design. METHODS: We performed a pooled analysis of all single-arm phase II studies in which a specific targeted agent (the anti-VEGF monoclonal antibody bevac...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Van Loon, Katherine, Espinoza, Anne M., Fogelman, David R., Wolff, Robert A., Javle, Milind M., Iyer, Renuka V., Picozzi, Vincent J., Martin, Ludmila Katherine, Bekaii-Saab, Tanios, Tempero, Margaret A., Foster, Nathan R., Kim, George P., Ko, Andrew H.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3955845/
https://ncbi.nlm.nih.gov/pubmed/24622062
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MPA.0000000000000095
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars